Crystalline form I of 3,4′5-trihydroxy-stilbene-3-β-D glucoside
US8575115B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2006 |
| Grant date | Nov 5, 2013 |
| Priority date | — |
| Expiry date | Apr 13, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel crystalline form of a Compound 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. Crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside of the present invention has a stable crystalline morphology, a definite melting point and a good chemical stability. Such a novel form of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside possesses the properties required for the preparation of solid formulations and is easily tabletable and readily formable when formulated, which allows for substantial decrease in raw materials costs, more facile operations in production and easier control over quality in industrial drug production, and moreover, better convenience in storage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.